MX2017009699A - Composicion de suspension oftalmica. - Google Patents
Composicion de suspension oftalmica.Info
- Publication number
- MX2017009699A MX2017009699A MX2017009699A MX2017009699A MX2017009699A MX 2017009699 A MX2017009699 A MX 2017009699A MX 2017009699 A MX2017009699 A MX 2017009699A MX 2017009699 A MX2017009699 A MX 2017009699A MX 2017009699 A MX2017009699 A MX 2017009699A
- Authority
- MX
- Mexico
- Prior art keywords
- ophthalmic
- suspension composition
- ophthalmic suspension
- suspension
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una suspensión incluye un ingrediente activo oftálmico suspendido en un vehículo de formulación que incluye un agente de suspensión y un derivado de celulosa no iónico. El agente activo oftálmico está presente como partículas que tienen Dv90 <5 µm y Dv50 <1 µm. La suspensión se puede administrar a un paciente para tratar una afección inflamatoria oftálmica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562107696P | 2015-01-26 | 2015-01-26 | |
| PCT/US2016/014872 WO2016123079A1 (en) | 2015-01-26 | 2016-01-26 | Ophthalmic suspension composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017009699A true MX2017009699A (es) | 2017-10-23 |
| MX390671B MX390671B (es) | 2025-03-21 |
Family
ID=55359733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017009699A MX390671B (es) | 2015-01-26 | 2016-01-26 | Composicion de suspension oftalmica. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10596107B2 (es) |
| EP (5) | EP3470059B1 (es) |
| JP (1) | JP2018507252A (es) |
| KR (1) | KR102538370B1 (es) |
| CN (1) | CN107427464B (es) |
| AU (4) | AU2016211745A1 (es) |
| BR (1) | BR112017016016B1 (es) |
| CA (1) | CA2975106A1 (es) |
| ES (5) | ES2966595T3 (es) |
| HU (5) | HUE048564T2 (es) |
| MX (1) | MX390671B (es) |
| PL (5) | PL4268850T3 (es) |
| PT (3) | PT4082531T (es) |
| SI (1) | SI4268850T1 (es) |
| WO (1) | WO2016123079A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3470059B1 (en) | 2015-01-26 | 2020-04-01 | Bausch & Lomb Incorporated | Ophthalmic suspension composition |
| US11000475B2 (en) | 2015-10-16 | 2021-05-11 | Sun Pharma Advanced Research Company Limited | Ophthalmic solution of difluprednate |
| LT3245988T (lt) | 2016-05-18 | 2024-02-12 | Sonikure Holdings Limited | Ultragarsu pagerinto transsklerinio vaistų pristatymo sistema |
| CA3073195A1 (en) | 2017-08-15 | 2019-02-21 | Nephron Pharmaceuticals Corporation | Aqueous nebulization composition |
| CA3112278A1 (en) * | 2018-09-21 | 2020-03-26 | Ps Therapy Ltd. | Artificial tear, contact lens and drug vehicle compositions and methods of use thereof |
| JP6994061B2 (ja) | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤 |
| US12600702B2 (en) * | 2019-02-15 | 2026-04-14 | Bausch + Lomb Ireland Limited | Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile and formulations thereof |
| US20230172946A1 (en) * | 2019-08-18 | 2023-06-08 | Iview Therapeutics, Inc. | In-situ Gel Forming Ophthalmic Formulations Containing Difluprednate |
| KR102271247B1 (ko) * | 2020-11-04 | 2021-06-30 | 삼천당제약주식회사 | 안과용 현탁액 조성물의 제조방법 |
| CN115887372A (zh) * | 2022-10-25 | 2023-04-04 | 苏州欧康维视生物科技有限公司 | 丙酸氟替卡松混悬液及其制备方法 |
| CN115554238A (zh) * | 2022-10-25 | 2023-01-03 | 苏州欧康维视生物科技有限公司 | 眼用混悬液及其制备方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4996335A (en) | 1980-07-10 | 1991-02-26 | Nicholas S. Bodor | Soft steroids having anti-inflammatory activity |
| US4540930A (en) | 1983-09-12 | 1985-09-10 | Wisconsin Alumni Research Foundation | Plywheel-powered mobile X-ray apparatus |
| ATE151286T1 (de) | 1983-11-14 | 1997-04-15 | Columbia Lab Inc | Bioadhäsive mittel |
| NZ226171A (en) | 1987-09-18 | 1990-06-26 | Ethicon Inc | Gel formulation containing polypeptide growth factor |
| IE63392B1 (en) | 1988-02-08 | 1995-04-19 | Insite Vision Inc | Ophthalmic suspensions |
| US5192535A (en) | 1988-02-08 | 1993-03-09 | Insite Vision Incorporated | Ophthalmic suspensions |
| US5124154A (en) | 1990-06-12 | 1992-06-23 | Insite Vision Incorporated | Aminosteroids for ophthalmic use |
| US5252318A (en) | 1990-06-15 | 1993-10-12 | Allergan, Inc. | Reversible gelation compositions and methods of use |
| CA2134376C (en) | 1993-12-20 | 2001-10-23 | Haresh G. Bhagat | Combinations of polymers for use in physiological tear compositions |
| US5556848A (en) * | 1993-12-27 | 1996-09-17 | Senju Pharmaceutical Co., Ltd. | Ophthalmic suspension containing diflupredonate |
| GB9718568D0 (en) * | 1997-09-03 | 1997-11-05 | Chauvin Pharmaceuticals Limite | Compositions |
| TWI227143B (en) | 1999-12-15 | 2005-02-01 | Guo-Jiun Sung | In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method |
| AR033151A1 (es) * | 2001-04-12 | 2003-12-03 | Sucampo Pharmaceuticals Inc | Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares |
| US7001615B1 (en) | 2001-12-07 | 2006-02-21 | Alcon, Inc. | Sustained release ophthalmic, otic and nasal suspension |
| EP2283864A1 (en) * | 2002-07-16 | 2011-02-16 | Elan Pharma International Ltd. | Liquid dosage compositions fo stable nanoparticulate active agents |
| CA2527712C (en) * | 2003-06-13 | 2014-08-05 | Alcon, Inc. | Ophthalmic compositions containing a synergistic combination of two polymers |
| US20050197303A1 (en) | 2003-10-31 | 2005-09-08 | Bausch & Lomb Incorporated | Combination of loteprednol etabonate and tobramycin for topical ophthalmic use |
| US20050182039A1 (en) * | 2004-02-13 | 2005-08-18 | Bausch & Lomb Incorporated | Use of Loteprednol etabonate for the treatment of dry eye |
| TWI358290B (en) | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
| US7919483B2 (en) | 2005-06-24 | 2011-04-05 | Medicis Pharmaceutical Corporation | Method for the treatment of acne |
| US20100234336A1 (en) | 2005-11-14 | 2010-09-16 | Erning Xia | Ophthalmic Compositions |
| US20120028947A1 (en) | 2005-11-14 | 2012-02-02 | Erning Xia | Ophthalmic Compositions |
| WO2007058935A2 (en) | 2005-11-14 | 2007-05-24 | Bausch & Lomb Incorporated | Ophthalmic composition for dry eye therapy |
| US8846770B2 (en) * | 2008-06-18 | 2014-09-30 | Otonomy, Inc. | Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders |
| US8501800B2 (en) | 2009-03-05 | 2013-08-06 | Insite Vision Incorporated | Controlled-release ophthalmic vehicles |
| CN101966143A (zh) | 2009-07-28 | 2011-02-09 | 胡容峰 | 加替沙星温度及pH敏感眼用凝胶的制备与应用 |
| KR101543613B1 (ko) | 2009-12-03 | 2015-08-11 | 알콘 리서치, 리미티드 | 카복시비닐 폴리머를 포함하는 나노입자 현탁액 |
| EP2758031A1 (en) | 2011-09-22 | 2014-07-30 | Bausch & Lomb Incorporated | Ophthalmic gel compositions |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| HK1208162A1 (en) | 2012-05-03 | 2016-02-26 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| CN111700880A (zh) | 2012-05-03 | 2020-09-25 | 卡拉制药公司 | 显示提高的粘膜转移的药物纳米粒子 |
| CN107880091B (zh) | 2012-05-08 | 2020-12-18 | 尼科斯眼药公司 | 疏水性治疗剂的制剂、其制备方法及应用 |
| US8765725B2 (en) * | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| WO2013169458A1 (en) | 2012-05-11 | 2013-11-14 | Bausch & Lomb Incorporated | Pharmaceutical compositions and methods for treating, controlling, ameliorating, or reversing conditions of dry eye |
| PL2848243T3 (pl) * | 2012-05-11 | 2024-04-08 | Activus Pharma Co., Ltd. | Nanoproszek związku organicznego, sposób wytwarzania i zawiesina |
| MX2015002208A (es) | 2012-08-31 | 2015-05-08 | Bausch & Lomb | Composiciones oftalmicas con acidos grasos omega-3. |
| US20150190407A1 (en) | 2014-01-07 | 2015-07-09 | Insite Vision Incorporated | Methods for treatment of postoperative inflammation with reduced intraocular pressure |
| JP6373995B2 (ja) | 2014-07-11 | 2018-08-15 | 富士フイルム株式会社 | 眼科用水性組成物 |
| WO2016006701A1 (ja) | 2014-07-11 | 2016-01-14 | 富士フイルム株式会社 | 眼科用水性組成物の製造方法及び眼科用水性組成物 |
| US10172852B2 (en) | 2014-07-28 | 2019-01-08 | Sun Pharma Advanced Research Company Ltd. | Method of increasing bioavailability and/or prolonging ophthalmic action of a drug |
| EP3470059B1 (en) | 2015-01-26 | 2020-04-01 | Bausch & Lomb Incorporated | Ophthalmic suspension composition |
-
2016
- 2016-01-26 EP EP18209003.5A patent/EP3470059B1/en active Active
- 2016-01-26 ES ES22175139T patent/ES2966595T3/es active Active
- 2016-01-26 PL PL23196938.7T patent/PL4268850T3/pl unknown
- 2016-01-26 PT PT221751399T patent/PT4082531T/pt unknown
- 2016-01-26 PL PL20166312.7T patent/PL3721868T5/pl unknown
- 2016-01-26 ES ES20166312T patent/ES2924645T5/es active Active
- 2016-01-26 EP EP20166312.7A patent/EP3721868B2/en active Active
- 2016-01-26 SI SI201631905T patent/SI4268850T1/sl unknown
- 2016-01-26 MX MX2017009699A patent/MX390671B/es unknown
- 2016-01-26 HU HUE18209003A patent/HUE048564T2/hu unknown
- 2016-01-26 PL PL16704744T patent/PL3250185T3/pl unknown
- 2016-01-26 CA CA2975106A patent/CA2975106A1/en not_active Abandoned
- 2016-01-26 WO PCT/US2016/014872 patent/WO2016123079A1/en not_active Ceased
- 2016-01-26 HU HUE20166312A patent/HUE059639T2/hu unknown
- 2016-01-26 ES ES16704744T patent/ES2704125T3/es active Active
- 2016-01-26 HU HUE22175139A patent/HUE066045T2/hu unknown
- 2016-01-26 US US15/006,525 patent/US10596107B2/en active Active
- 2016-01-26 KR KR1020177023453A patent/KR102538370B1/ko active Active
- 2016-01-26 CN CN201680016825.XA patent/CN107427464B/zh active Active
- 2016-01-26 PL PL22175139.9T patent/PL4082531T3/pl unknown
- 2016-01-26 PT PT231969387T patent/PT4268850T/pt unknown
- 2016-01-26 ES ES23196938T patent/ES3031414T3/es active Active
- 2016-01-26 BR BR112017016016-1A patent/BR112017016016B1/pt active IP Right Grant
- 2016-01-26 EP EP23196938.7A patent/EP4268850B1/en active Active
- 2016-01-26 HU HUE16704744A patent/HUE041945T2/hu unknown
- 2016-01-26 JP JP2017558359A patent/JP2018507252A/ja active Pending
- 2016-01-26 EP EP16704744.8A patent/EP3250185B1/en not_active Revoked
- 2016-01-26 PT PT201663127T patent/PT3721868T/pt unknown
- 2016-01-26 AU AU2016211745A patent/AU2016211745A1/en not_active Abandoned
- 2016-01-26 PL PL18209003T patent/PL3470059T3/pl unknown
- 2016-01-26 HU HUE23196938A patent/HUE071679T2/hu unknown
- 2016-01-26 EP EP22175139.9A patent/EP4082531B1/en active Active
- 2016-01-26 ES ES18209003T patent/ES2787039T3/es active Active
-
2020
- 2020-03-23 US US16/826,366 patent/US11534395B2/en active Active
-
2021
- 2021-05-12 AU AU2021203027A patent/AU2021203027B2/en active Active
-
2022
- 2022-12-21 US US18/086,286 patent/US12589069B2/en active Active
-
2023
- 2023-10-12 AU AU2023248145A patent/AU2023248145B2/en active Active
-
2025
- 2025-11-24 AU AU2025271194A patent/AU2025271194A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017016016A2 (pt) | composição de suspensão oftálmica | |
| CL2019003432A1 (es) | Composición farmacéutica oftálmica que comprende nanopartículas mucopenetrantes, cuyo núcleo comprende un agente activo farmacéutico seleccionado entre un inhibidor de ciclooxigenasa (cox) o un fármaco antiinflamatorio no esterioidal (aine), y está recubierto con un polímero modificador de superficie; y uso para tratar un trastorno del ojo (divisional de solicitud cl 2956-2014). | |
| MX384021B (es) | Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones. | |
| BR112014014832A8 (pt) | formulação e método de controlar fungos | |
| BR122021018243A8 (pt) | Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável | |
| CR20170393A (es) | Encapsulado de agentes activos de alta potencia | |
| CR20140365A (es) | Compuestos de carbamato y preparación y uso de los mismos | |
| HK1205461A1 (zh) | 用於眼部传输治疗剂的组合物和方法 | |
| CO2017001493A2 (es) | Kits que comprenden inhibidores tigit y agentes anticáncer | |
| CL2015003072A1 (es) | Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas. | |
| MX2018000285A (es) | Composicion para desobstruir la nariz congestionada que tiene actividad antiviral. | |
| AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
| BR112015011743A2 (pt) | conservantes | |
| MX390100B (es) | Suspension acuosa que contiene nanoparticulas de glucocorticosteroide. | |
| CL2017000120A1 (es) | Composiciones en suspensión de ciclosporina a para inyecciones subconjuntivales y perioculares | |
| SV2017005603A (es) | Formulacion solida oral que contiene irinotecan y metodo de preparacion de la misma | |
| MX2016005764A (es) | Formulacion en suspension acuosa que comprende nanoparticulas de antibioticos macrolidos. | |
| BR112016017897A8 (pt) | uso de composto de carboxamida heterocíclica de diamino no tratamento de câncer relacionado ao axl, composição farmacêutica e combinação | |
| MX366277B (es) | Composiciones de agente activo retinoide particuladas, secas y finas y formulaciones topicas que incluyen las mismas. | |
| CL2015001748A1 (es) | Formulaciones antiparasitarias transdermicas | |
| CL2015002817A1 (es) | Formulación del l-5-metiltetrahidrofolato de calcio amorfo (l-5-mthf-ca). | |
| NZ767710A (en) | Ocular formulations for drug-delivery and protection of the anterior segment of the eye | |
| CL2012001835A1 (es) | Uso de una formulacion que comprende un agente viscogenico y moxifloxacina para preparar un medicamento util para tratar el oido medio. | |
| MX2018000021A (es) | Composiciones multifasicas. | |
| MX2015012716A (es) | Composiciones para el uso en el tratamiento de trastornos oculares que usan dipiridamol. |